Anzeige
Mehr »
Sonntag, 19.10.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Investing.com

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
17:06Israel stocks lower at close of trade; TA 35 down 1.14%
15:18DS-3939 shows promising results in early trials against solid tumors
15:06Raludotatug deruxtecan shows 50.5% response rate in ovarian cancer trial
14:54Saudi Arabia stocks lower at close of trade; Tadawul All Share down 0.05%
14:18RAPT Therapeutics to report phase 2 trial data for urticaria drug
12:06US semis & hardware: Two years into the AI boom - who has benefited most?
11:18'Best houses in a tough neighbourhood,' Morgan Stanley upbeat on UK stocks
11:185 big analyst AI moves: Nvidia, AMD upgraded; ASML seen on €1,000 path
10:30Pancreatic cancer drug shows 41% response rate in clinical trial
10:18Can MSCI India weight converge with China's?
10:18These analysts say the AI spending boom is "not too big." Here's why.
SaRussia stocks lower at close of trade; MOEX Russia Index unchanged
SaKelun-Biotech's breast cancer drug shows promising phase 3 results
SaENHERTU shows 92% invasive disease-free survival rate at three years in breast cancer trial
SaESMO 2025: enhertu shows highest pCR rate in HER2+ early breast cancer
SaIs it really a "Golden Age of Construction"?
SaCould weight-loss drugs hit restaurant sales? UBS weighs in.
SaFederal leverage over Fannie, Freddie could shape Trump's housing push
SaHow OpenAI deal can make Walmart a trillion dollar market cap company
SaWill Q3 earnings rescue European equities as 2026 looms?
SaPension reform can be the catalyst to transform European markets - Morgan Stanley
SaGedatolisib shows strong results in breast cancer trial
SaCelcuity reports positive Phase 1 data for prostate cancer therapy
SaCelcuity completes enrollment for PIK3CA mutant cohort in phase 3 trial
SaIs Meta facing its Alphabet-ChatGPT moment?